A major downside of targeting specifically G12C is that, despite accounting for about 50% of all KRAS mutations in lung cancer, it is not the most frequent amino acid change in CRC and pancreatic cancers, representing approximately 15% and 2% of all KRAS mutations found in these tumors, respectively [2]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.